odalasvir + simeprevir + ritonavir + danoprevir

A four-drug oral combination of **odalasvir**, **simeprevir**, **ritonavir**, and **danoprevir** intended as an investigational regimen for the treatment of chronic hepatitis C virus (HCV) infection. - **Odalasvir** is an NS5A inhibitor that disrupts viral replication complex assembly in hepatitis C virus. - **Simeprevir** and **danoprevir** are NS3/4A protease inhibitors that prevent viral polyprotein processing. - **Ritonavir** is a pharmacokinetic booster (CYP3A inhibitor) used to enhance the plasma levels of danoprevir and reduce its metabolism. The rationale for this combination is to provide multiple direct-acting antiviral mechanisms for potent, short-duration HCV therapy, bolstered by ritonavir’s boosting of danoprevir pharmacokinetics. This specific four-drug combination has not been widely reported in clinical trials, but similar regimens involving odalasvir plus simeprevir and/or danoprevir+ritonavir have demonstrated efficacy against HCV in early-phase studies[1][2]. Developers and manufacturers, as well as detailed phase information for this exact four-drug combination, remain undetermined. However, odalasvir and simeprevir have been developed by Janssen (now part of Johnson & Johnson), danoprevir by Ascletis, and ritonavir by AbbVie. The modalities represented are all small molecule drugs.